Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer
about
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyPeptides and peptidomimetics as immunomodulators.Classification of current anticancer immunotherapiesAnti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyNuclear Factor of Activated T Cells-dependent Down-regulation of the Transcription Factor Glioma-associated Protein 1 (GLI1) Underlies the Growth Inhibitory Properties of Arachidonic Acid.Trial watch: DNA vaccines for cancer therapy.Metronomics: towards personalized chemotherapy?Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362.Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer.
P2860
Q26824462-AF133716-F3A7-48BB-B05C-69A91168F6A5Q34359984-F99FDFF5-AAF7-4DC5-8FDA-F0D53FC4C527Q35149637-DB69A62F-035F-4388-9845-D1A82BF79724Q36101895-CBB6E031-074B-4CA1-ABDE-915515AD15B7Q36116250-6E336C9F-EEE2-4764-B6A9-8D11EFB8ED18Q36489326-3CAABCF7-7C1C-4A1F-88E4-7B83C72A8F03Q36845824-D8DD7743-AE85-4F2E-BA8A-D2B7B5818F34Q38218923-D8D2435B-2902-4183-9511-EB240EBB807FQ39015610-636C0D99-8B73-43C8-B807-037521F62B91Q42107855-14B70D89-A397-4CA0-880F-19D4257A3646Q46388405-25325788-1265-479E-A6DE-460A5898D016Q48140622-7AC6B3C8-7B77-4DCA-8323-7066FAE4BF57Q52879616-DF374A29-9F45-442A-9A7B-34EAD4870565Q55262619-5B6C0033-9080-46FC-B76D-DAF510AE6891
P2860
Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immunotherapy with HER-2 and V ...... models of human breast cancer
@ast
Immunotherapy with HER-2 and V ...... models of human breast cancer
@en
type
label
Immunotherapy with HER-2 and V ...... models of human breast cancer
@ast
Immunotherapy with HER-2 and V ...... models of human breast cancer
@en
prefLabel
Immunotherapy with HER-2 and V ...... models of human breast cancer
@ast
Immunotherapy with HER-2 and V ...... models of human breast cancer
@en
P2093
P2860
P356
P1433
P1476
Immunotherapy with HER-2 and V ...... models of human breast cancer
@en
P2093
Kevin C Foy
Megan J Miller
Nicanor Moldovan
Pravin T P Kaumaya
Tatjana Bozanovic
William E Carson
P2860
P304
P356
10.4161/ONCI.21057
P577
2012-10-01T00:00:00Z